Jason Hall partners with clients to develop US and global policy assessments and strategies designed to improve access, with a focus on vaccines and infectious disease medicines.

He has broad product development and commercialization experience across infectious diseases, including influenza, respiratory syncytial virus (RSV) infections, and COVID-19, and is committed to finding innovative ways to engage key stakeholders and inform policy recommendations and guidelines that help deliver products to patients.

Prior to joining Avalere, Jason worked at AstraZeneca, where he held several roles during his 15-year tenure. Most recently, he served as the global commercial head, Vaccines and Infectious Disease, responsible for developing and implementing influenza and RSV brand, market access, and policy strategies, including influenza pandemic preparedness. He also developed long-range plans and commercialization strategies for COVID-19 vaccines and monoclonal antibody therapies.

Jason also worked closely with clinical and medical stakeholders and advocacy groups to generate scientific and real-world evidence that supported recommendation decisions through the Center for Disease Control’s (CDC) Advisory Committee on Immunization Practices and similar agencies outside the US. Prior to that, Jason led the market access, government pricing, and contract strategy teams within the Infection group at MedImmune/AstraZeneca, including the CDC’s Vaccines for Children Program within the company.

Jason has an MBA from the George Washington University and a BA in biology from Augustana College.

Authored Content

Join us for a live conversation exploring actionable strategies for driving greater vaccine access and adoption.

Stakeholders in the COVID-19 pandemic response face regulatory and commercial uncertainties as emergency operations transition and market access of products face both emergency use and full licensure.

The COVID-19 pandemic response has increased investment in vaccine innovations, but also exposed gaps in US and global vaccine access and delivery.

On May 5, the Biden administration announced its support for waiving World Trade Organization (WTO) intellectual property regulations with respect to COVID-19 vaccines, in an effort to increase supply and worldwide access to the vaccines.

Tune into another episode of Start Your Day with Avalere. In this segment, experts from our vaccines team discuss the general outlook for the vaccines marketplace and pipeline.